Tarsus Pharmaceuticals released positive data from the pivotal Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis. The trial…
Biogen announced topline results from the Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The…
Novartis reported one year results of the Phase 3 MERLIN study, assessing the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg versus Eylea (aflibercept) 2 mg…
Important glaucoma-based research led by investigators at NYU Grossman School of Medicine reveals that a chemical known to protect nerve cells actually slows down the…
Genentech announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, for the treatment…
Ocuphire Pharmaceuticals announced that results from its ORION-1 Phase 2 clinical trial evaluating the safety and efficacy of Nyxol in glaucoma and presbyopia have been published…
Bausch + Lomb announced that the results from the Phase 2 SEECASE clinical study, evaluating NOV03 (perfluorohexyloctane) ophthalmic solution in patients with Dry eye disease…
In a recent special piece for Ophthalmology Times Dr. Jason R. Chin with Andover Eye (Andover, MA) and Dr. Gary W. Jerkins, president and principal…
Researchers are developing a powerful, new kind of patient registry by using optical coherence tomography, angiography, and ultra-widefield fundus photography. The Duke Neurodegenerative Disease Retinal…
Enthera Pharmaceuticals announced the completion of a €28 million Series A financing round co-led by seed investor Sofinnova Partners and incoming investor AbbVie. Additional contributors…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
